Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide.
Langerhans cell histiocytosis (LCH) has previously been reported in association with other malignancies. The pathogenesis of LCH and its relationship to other malignancies is poorly understood. We present a novel case of a child who developed an LCH bone lesion while receiving a Phase I protocol therapy with oral fenretinide/Lym-X-Sorb (4-HPR/LXS) powder for neuroblastoma.
Rayburg
Melissa
M
Division of Hematology/Oncology, Cincinnati Children's Hospital, Cincinnati, Ohio 45249, USA.
Towbin
Alexander
A
Yin
Hong
H
Maugans
Todd
T
Maurer
Barry
B
Nagarajan
Rajaram
R
Weiss
Brian
B
D001859:Bone Neoplasms / Q000209:etiology; D002648:Child; D017313:Fenretinide / Q000627:therapeutic use*; D006646:Histiocytosis, Langerhans-Cell / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D006801:Humans; D008297:Male; D009447:Neuroblastoma / Q000150:complications* / Q000188:drug therapy
D017313:Fenretinide